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Abstract. Glioblastoma is the most common malignant central 
nervous system tumor. Patient outcome remains poor despite 
the development of therapy and increased understanding of 
the disease in the past decades. Glioma cells invade the peri-
tumoral brain, which results in inevitable tumor recurrence. 
Previous studies have demonstrated that the extracellular 
matrix (ECM) is altered in gliomas and serves a major role 
in glioma invasion. The present study focuses on differences 
in the ECM composition of tumors in patients with poor and 
improved prognosis. The mRNA and protein expression of 
16 invasion-associated ECM molecules was determined using 
reverse trascription-quantitiative polymerase chain reaction 
and immunohistochemistry, respectively. Clinical factors of 
patients with different prognoses was also analyzed. It was 
determined that age and postoperative Karnofsky performance 
score were associated with patient survival. Furthermore, 
Fms-related tyrosine kinase 4/vascular endothelial growth 
factor receptor 3 (FLT4/VEGFR3), murine double minute 
2 (MDM2) and matrix metallopeptidase 2 (MMP2) mRNA 
levels were significantly different between the two prognostic 
groups. Additionally, brevican, cluster of differentiation 44, 
hyaluronan mediated motility receptor, integrin-αV and -β1, 
and MDM2 protein expression were indicated to be signifi-
cantly different in immunohistochemistry slides. Using the 
expression profile, including the invasion spectrum of the 
samples, it was possible to identify the prognostic group of 
the sample with high efficacy, particularly in cases with 
poor prognosis. In conclusion, it was determined that ECM 
components exhibit different expression levels in tumors with 
different prognoses and thus the invasion spectrum can be 
used as a prognostic factor in glioblastoma.
Introduction
Glioblastoma is a disease with a notably poor prognosis, 
with a 2-year prognosis is as low as 27% in Europe and in 
the United States (1,2). Patients undergo concurrent chemo-
radiation following tumor resection, and then chemotherapy, 
namely alkylating agent temozolomide, is administered as 
monotherapy. Currently, only bevacizumab, an anti-vascular 
endothelial growth factor (VEGF) antibody, is available as 
a targeted therapy (2-4). Despite the changes in treatment 
protocols in the past decade and the extensive research in 
the field of glioblastoma treatment options, the majority of 
patients succumb 16‑24 months after diagnosis (1‑4). Specific 
clinical factors affect patient outcome, including sex, age, 
Karnofsky performance status (KPS) score and tumor size, 
but these are poor predictors of prognosis and cannot be used 
successfully in everyday clinical practice (5,6). Maximum 
safe resection may improve patient survival; however, neither 
the minimal cut-off resection volume nor the maximum 
residual tumor volume that is associated with survival benefit 
has been established (7).
The molecular pathology of glioblastomas has been the 
focus of recent research (8-13). Certain well-established 
alterations in tumors, including methylation of the 
O-6-methylguanine-DNA methyltransferase (MGMT) 
promoter region, isocitrate dehydrogenase (IDH) 1/2 or telom-
erase reverse transcriptase mutations, epidermal growth factor 
receptor (EGFR) amplification or the well‑known variant III 
mutation, are also associated with prognosis (14). IDH muta-
tions have a notable impact on patient outcome; however, they 
are present in <10% of glioblastomas (15,16). MGMT promoter 
methylation status is associated with the effectiveness of the 
current standardly used temozolomide chemotherapy, but 
alterations in the methylation status during treatment is a 
known phenomenon (9). Currently, clinicians have no means 
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of assessing the prognosis of individual patients, even though 
there would be a demand for identifying patient subgroups 
with different survival chances. Identifying patients that 
require more frequent follow-up examinations to detect tumor 
recurrence and determining subgroups that would benefit less 
from the aggressive treatment protocol currently used, or that 
would be fit for targeted therapy, is currently not possible for 
the majority of clinicians.
Peritumoral infiltration is a hallmark of all diffusely 
growing glioma types, therefore glioblastomas are also 
invasive (10). Tumor masses have no clear macroscopic 
border, thus complete surgical resection is not possible (7). 
The extracellular matrix (ECM) is known to be an important 
determinant of glioma invasion. Previous studies revealed 
alterations in the expression of specific ECM components 
in glioblastoma compared with that in non-tumor brain or 
grade II-III astrocytomas (17-20). Certain inhibitors targeted 
against specific ECM components have been previously tested 
in clinical trials, but have failed to provide a breakthrough in 
glioblastoma treatment thus far (1,4,21-23). A selected group of 
ECM-associated molecules, also known as an invasion panel, 
was tested in previous studies to understand the molecular 
behavior of glioblastoma. The expression pattern of these 
molecules, including the invasion spectrum, was demonstrated 
to be specific for primary and secondary tumors, as well as 
the grade of astrocytomas (24-26). Furthermore, it is consid-
ered that the molecular composition of glioblastoma ECM 
contributes to invasiveness; thus, the molecular fingerprint of 
the tumor is associated with the efficacy of conventional and 
targeted therapies. For example, matrix metallopeptidase 2 
(MMP2) and MMP9 molecules are associated with increased 
invasiveness in glioblastoma. Integrin-αV (ITGAV) is known 
to be involved in the migration of glioma cells and is thus 
considered to contribute to invasiveness. Other examples 
include the hyaluronan receptor cluster of differentiation 
(CD)44, or the central nervous system‑specific proteoglycan 
brevican (BCAN), which have been associated with increased 
invasiveness (24,27-29). The aim of the present study was to 
analyze the expression pattern of the invasion panel in glio-
blastoma samples, and to identify the association between the 
invasion spectrum and disease progression.
Patients and methods
Patients and tumor samples. Samples from 132 adult 
(58 females and 74 males) patients who were diagnosed 
with primary glioblastoma between 01 January 2006 and 
31 December 2015 were selected from the Brain Tumor 
and Tissue Bank of the Department of Neurosurgery, 
University of Debrecen (Debrecen, Hungary). Stratified 
random sampling was performed, with overall survival 
time as stratum. No other parameter was considered when 
selecting samples. The tumor samples were all obtained 
from brain lobes, and were frozen intraoperatively on the 
surface of liquid nitrogen and then stored at ‑78˚C in a deep 
freezer until use for mRNA analysis. The rest of the resected 
tumor was fixed in 10% paraformaldehyde solution at 25˚C 
for 24 h and then embedded in paraffin. The tissues were 
examined, and the diagnosis of glioblastoma was made by 
an experienced neuropathologist. Patients had been treated 
with radiotherapy plus concomitant and maintenance temo-
zolomide chemotherapy following maximal safe resection 
of the tumor. Upon tumor recurrence, patients received 
bevacizumab monotherapy until further progression. Patient 
age ranged from 20 to 82 years, median age was 60 years 
[confidence interval (CI), 58.0‑62.0 years], and the mean 
postoperative KPS score was 82.5 (CI, 80.4-84.7). Overall 
mean survival (OS) time of the patients was 20.8 months 
(CI, 17.6-24.0 months). Patients were divided into two 
prognostic groups based on OS time. Patients whose OS 
time was <24 months were considered to be ‘patients with 
a worse prognosis’ and were placed in group A (n=74), 
whereas patients whose OS time was ≥24 months were 
considered to be ‘patients with a better prognosis’ and 
were placed in group B (n=58). The 24-month threshold 
was selected as a previously published analysis of patient 
data at our institution (University of Debrecen Clinical 
Center, Department of Neurosurgery, Department of 
Table I. List of the analyzed ECM components.
Symbol Assay ID
BCAN BCAN-Hs00222607_m1
CD44 CD44-Hs01075861_m1
CSPG5 CSPG5-Hs00198108_m1
EGFR EGFR-Hs01076090_m1
FLT4/VEGF3 FLT4-Hs00176607_m1
HMMR HMMR-Hs00234864_m1
IDH1 IDH1-Hs01855675_s1
ITGAV ITGAV-Hs00233808_m1
ITGB1 ITGB1-Hs00559595_m1
ITGB5 ITGB5-Hs00174435_m1
MDM2 MDM2-Hs01066930_m1
MMP-2 MMP2-Hs01548727_m1
NCAN NCAN-Hs00189270_m1
PDGFA PDGFA-Hs00964426_m1
TNC TNC-Hs01115665_m1
VCAN VCAN-Hs00171642_m1
GFAP GFAP-Hs00909233_m1
MKI67 MKI67-Hs01032443_m1
B2M B2M-Hs00187842_m1
GAPDH GAPDH-Hs99999905_m1
A total of 16 invasion-associated ECM molecules were selected for 
Taqman Low Density Arrays. GFAP and MKI67 were used for quality 
control of the samples. B2M and GAPDH were used as housekeeping 
genes, and B2M was selected as the reference gene for relative gene 
expression analyses. ECM, extracellular matrix; BCAN, brevican; 
CD44, cluster of differentiation 44; CSPG5, chondroitin sulfate 
proteoglycan 5; EGFR, epidermal growth factor receptor; FLT4, 
Fms-related tyrosine kinase 4; HMMR, hyaluronan-mediated motility 
receptor; IDH1, isocitrate dehydrogenase 1; ITGAV, integrin-αV; 
MDM2, murine double minute 2; MMP-2, matrix metallopeptidase 
2; NCAN, neurocan; PDGFA, platelet-derived growth factor α; TNC, 
tenascin C; VCAN, versican; VEGF, vascular endothelial growth 
factor; GFAP, glial acidic fibrillary protein; MKI67, marker of prolif-
eration Ki-67; B2M, β2 microglobulin.
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Oncology, Debrecen, Hungary) determined that patients 
previously treated according to Stupp's protocol (60 Gy 
irradiation with concurring 75 mg/d/m2 temozolomide, 
followed by 150-200 mg/d/m2 temozolomide monotherapy 
until progression), then receiving bevacizumab following 
disease progression have a mean OS time of 24 months (24). 
Literature data also supported that an OS of ≥24 months can 
be considered to represent better than average survival (5,30).
Determination of the invasion spectrum. The invasion spec-
trum was determined by measuring the mRNA expression level 
of the 16 molecules of the invasion panel. Ki-67 was measured 
to confirm presence of tumor tissue, GFAP was measured 
to confirm glial origin. (Table I). The mRNA expression 
was determined through reverse transcriptase-quantitative 
polymerase chain reaction (RT-qPCR), as described previ-
ously (31,32). Flash‑frozen tissue samples were first pulverized 
and then homogenized using TriReagent® (Invitrogen; Thermo 
Fisher Scientific, Inc., Waltham, MA, USA) at 25˚C until no 
visible solid tissue was present in the tubes. Total RNA was 
isolated from TriReagent lysates, according to the manufac-
turer's protocols. A NanoDrop® ND-1000 Spectrophotometer 
(NanoDrop Technologies; Thermo Fisher Scientific, Inc., 
Wilmington, DE, USA) was used to measure the quantity and 
purity of the RNA. Subsequently, reverse transcription was 
performed to convert total RNA to single-stranded comple-
mentary DNA (cDNA) with a High-Capacity cDNA Archive 
kit with RNasin (Applied Biosystems; Thermo Fisher 
Scientific, Inc.). The cDNA was then loaded onto a microflu-
idic card (cDNA from 100 ng of total RNA/port). An Applied 
Biosystems 7900HT real-time PCR system with Micro Fluidic 
Card upgrade (Applied Biosystems; Thermo Fisher Scientific, 
Inc.) was used to perform TaqMan® low-density array experi-
ments. The thermocycling conditions were 2 min at 50˚C, 
10 min at 94.5˚C, followed by 40 cycles of denaturation at 97˚C 
for 30 sec and annealing and extension at 60˚C for 1 min. The 
Micro Fluidic Cards were analyzed with SDS 2.1 software 
(Applied Biosystems; Thermo Fisher Scientific, Inc.) as rela-
tive quantification studies, and the cycle quantification (Cq) 
values were exported for further analysis. β2 microglobulin 
and GAPDH housekeeping genes exhibited the least variation 
among the samples, and β2 microglobulin was used as refer-
ence gene to calculate the ∆Cq value for each gene. Expression 
values were calculated using the comparative Cq method, as 
described previously (33).
Immunohistochemistry. Protein expression was measured 
by immunohistochemical staining of formalin-fixed 
paraffin embedded tissue slides. For the slides, the corre-
sponding tissue blocks were collected from the Department 
of Neuropathology, Institute of Pathology, University of 
Debrecen. Sections (4 µm) were cut with a microtome then 
prepared for staining. Sections were first deparaffinized 
using xylene, then rehydrated in a graded series (100%, 
then 95%) of ethanol at 25˚C. Epitopes were retrieved 
by heat-induction in citrate buffer (pH 6.0, Antigen 
Decloaker 10X, Biocare Medical, LLC, Pacheco, CA, USA). 
Endogenous peroxidase activity was blocked with 0.3% 
methanolic hydrogen‑peroxide at 25˚C for 10 min prior 
to the slides being incubated overnight with the primary 
antibodies in concentrations according to manufacturer's 
protocols. (Table II) Visualization was conducted with a 
MACH 4 Universal AP Polymer kit (Biocare Medical, LLC, 
Paheco, CA, USA) according to manufacturer's protocol and 
3,3'-diaminobenzidine with hematoxylin counterstaining 
at 25˚C for 10 min and 30 secs, respectively. Positive and 
negative control slides were also stained using the same 
procedures as the other slides (Table II). Expression of the 
proteins was evaluated by three independent observers in 
10 random high‑power fields (x100 magnification, Eclipse 
80i microscope, Nikon, Minato, Tokyo, Japan) in each slide 
in a semi-quantitative manner, considering the percentage 
of staining cells and/or extracellular space, as well as the 
intensity of staining. The percentage of the staining was 
considered as follows: 0, negative or <10% staining; 1, 
10-25% staining; 2, 26-50% staining; 3, 51-75% staining; and 
4, >75% staining, as described by Bondarendko et al (34). 
Intensity was graded from 0-3 (negative, -; weak positivity, 
+; moderate positivity, ++; and strong positivity, +++, 
respectively). Combined scores were calculated for each 
slide by multiplying the scores, and a mean score for each 
sample was then determined.
Table II. Primary antibodies used for immunohistochemical staining.
Protein Antibody code Manufacturer Dilution Positive control
Brevican NBP1-89992PEP Novus Biologicals (Littleton, CO, USA) 1:200 Rat brain
CD 44 AB16728 Abcam (Cambridge, United Kingdom) 1:500 Human tonsil
CSPG-5 (neuroglyan C) ORB157961 Biorbyt (Cambridge, United Kingdom) 1:250 Rat brain
Flt-4/VEGFR-3 SC-514825 Santa Cruz Biotechnology (Dallas, TX, USA) 1:250 Human kiney
HMMR (CD168, RHAMM) AB110075 Abcam (Cambridge, United Kingdom) 1:200 Human tonsil
Integrin alpha V chain BS-2203R Bioss Antibodies (Woburn, MS, USA) 1:250 Human kidney
Integrin beta 1 chain RD-MAB1778-SP RnD Systems (Minneapolis MN, USA 1:250 Human tonsil
Integrin beta 5 chain NBP1-88117 Novus Biologicals (Littleton, CO, USA) 1:250 Human tonsil
MDM2 AB16895 Abcam(Cambridge, United Kingdom) 1:400 Rat brain
MMP-2 TA806846 OriGene Technologies (Rockville, MD, USA) 1:200 Human tonsil
Versican AB177480 Abcam (Cambridge, United Kingdom) 1:150 Rat brain
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Statistical analysis. Independent samples Student's paired 
t-test and Mann-Whitney U tests were used for age, tumor size, 
KPS values, RNS and protein expression, while χ2 test was 
used for sex, tumor location and percentage of repeat surgery 
patients. Progression-free survival (PFS) and OS times were 
compared using Kaplan-Meier survival analysis with log-rank 
(Mantel-Cox) test. PFS and OS times were calculated from the 
time of diagnosis. For an overall analysis of the expressional 
pattern, the statistical classifier nearest neighbor search was used 
on mRNA expression data (35,36). The nearest neighbor search 
analyzed all attributes (i.e. the level of expression of a given 
ECM molecule) at the same time and compared these attributes 
to those of other samples, finding similar patterns of mRNA 
expression among the samples. The value of every measured 
ECM component were used to identify samples that have the 
most similar values. Samples with similar patterns of expression 
were then put in the same group. P<0.05 level of significance 
was considered as statistically significant. Calculations were 
performed using statistical program GraphPad Prism v6.01 
(GraphPad Software Inc., La Jolla, CA, USA). Nearest neighbor 
search was performed using statistical program Weka v3.6 
(University of Waikato, Hamilton, New Zealand).
Results
Patient data. The clinical characteristics of the patients are 
summarized in Table III. The median ages of the patients was 
61.0 years (CI, 57.97-63.28 years) in group A and 58.5 years 
(CI, 55.53-61.47 years) in group B. Statistical analysis revealed 
a significant difference between the two groups (P=0.0293). 
Patients had an improved preoperative and postoperative KPS 
score in group B compared with patients in group A, but the 
KPS scores did not differ significantly. The other examined 
clinical characteristics of the tumors were not statistically 
different in the two groups: the tumors were determined to be 
similar in size in the two groups and there was no statistical 
difference in the involvement of the dominant side of the 
brain nor the lobular localization of the tumor. Kaplan-Meier 
analyses confirmed the predicted differences in PFS and OS 
of the patients in groups A and B. The median OS time was 
9.0 months (CI, 8.14-9.86 months) in group A, while patients in 
group B had a significantly improved prognosis with a median 
Figure 1. Kaplan-Meier survival analysis of patients with glioblastoma with 
different disease prognoses. Patients in group A had significantly reduced OS 
time compared with those in group B. Group A, OS <24 months; group B, OS 
>24 months; OS, overall survival.
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OS time of 27.0 months (CI, 22.17-31.83 months) (P<0.0001). 
The median PFS differences were less notable but remained 
statistically significant, with 5.5 months (CI, 3.79‑7.21 months) 
in group A and 8.5 months (4.36-12.64 months) in group B 
(P=0.024). Fig. 1 depicts the OS differences between groups A 
and B. The two groups therefore had no major differences in 
the clinical characteristics of the patients apart from patient 
age and the survival times, which were selection criteria.
mRNA expression of the tumor samples. Ki-67 mRNA was 
measured in each sample to confirm that the flash-frozen 
samples contained sufficient tumor tissue. All the samples 
were determined to express sufficient marker of proliferation 
Ki-67 (MKI67) and the two groups did not demonstrate any 
significant difference in Ki‑67 expression (P=0.8567). GFAP 
expression was also analyzed to confirm the presence of glial 
tumors.
The mRNA expression of the invasion-associated ECM 
components in the two prognostic groups demonstrated notable 
differences. Fig. 2 depicts the mean mRNA expression values 
of the analyzed molecules. Using the independent samples 
Student's t-test, 3 invasion-associated molecules demonstrated 
Figure 2. Invasion spectrum (the mRNA expression pattern of invasion-associated extracellular matrix components) differs in patients with ‘worse’ and ‘better’ 
prognoses. mRNA expression measurements were performed twice for each gene to confirm the data. A longer bar on the logarithmic scale indicates reduced 
expression. *P<0.05 vs. group A (Mann-Whitney U test). Group A, OS <24 months; group B, OS >24 months; BCAN, brevican; CD44, cluster of differentiation 
44; CSPG5, chondroitin sulfate proteoglycan 5; EGFR, epidermal growth factor receptor; FLT4, Fms-related tyrosine kinase 4; HMMR, hyaluronan-mediated 
motility receptor; IDH1, isocitrate dehydrogenase 1; ITGAV, integrin-αV; MDM2, murine double minute 2; MMP-2, matrix metallopeptidase 2; NCAN, 
neurocan; PDGFA, platelet-derived growth factor α; TNC, tenascin C; VCAN, versican; OS, overall survival.
Figure 3. A total of 3 invasion‑associated extracellular matrix components demonstrated significantly different expression levels in the samples from different 
prognostic groups. All 3 molecules had increased expression in patients in group A, indicating that the level of these molecules was associated with tumor 
invasiveness and patient survival. Group A, OS <24 months; group B, OS >24 month.; FLT4, Fms-related tyrosine kinase 4; MDM2, murine double minute 2; 
MMP-2, matrix metallopeptidase 2; rel., relative; OS, overall survival.
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significant differences between the two prognostic groups. 
Fms-related tyrosine kinase 4 (FLT4), murine double minute 
2 (MDM2) and MMP2 expression levels were significantly 
increased in patients in group A compared with those in 
group B (P=0.0285, P=0.0200 and P=0.0023, respectively). 
Fig. 3 depicts the expression of these 3 ECM components in 
the different prognostic groups.
Immunohistochemistry confirms different ECM composition 
in tumors with different prognoses. Immunohistochemistry 
sections were analyzed and differences in protein expression 
were identified in the different glioblastoma prognostic groups. 
Out of the analyzed invasion-associated proteins, BCAN 
(P=0.0002), CD44 (P=0.0200), hyaline-mediated motility 
receptor (P=0.0020), ITGAV and -β1 (P=0.0200 and 0.0400, 
respectively), and MDM2 (P=0.0240) were determined to be 
significantly different between the two groups. The mRNA 
and immunohistochemical differences were concordant 
in direction except for ITGβ1 molecules. Concordance of 
protein expression underlines the relevance of the mRNA 
expression data. Table IV contains the immunohistochem-
istry scores and P‑values of the significant ECM molecules. 
Immunohistochemical slides of the ECM components that 
were significant at the mRNA level are presented in Figs. 4‑6.
Statistical classifier selects molecules that differentiate tumors 
with worse and better prognoses. Subsequent to analyzing 
mRNA and protein expression for each ECM component indi-
vidually, a nearest neighbor search, a statistical classifier to 
perform joint, overall analysis of the invasion panel, was used. 
The following molecules were used by the statistical classifier 
algorithm as major influencers: CD44, EGFR, FLT4/VEGF-3, 
IDH1, MMP2, platelet-derived growth factor α, tenascin C 
and versican.
The expression of these ECM components may be a key 
component in the separation of tumors with different prog-
noses. The classifier identified the prognosis, including whether 
the patient lived ≥24 months, in 94/132 patients correctly. 
Sensitivity and positive predictive values were increased 
in tumors with a worse prognosis. The method's receiver 
operating curve (ROC) area, which is the curve of sensitivity 
dotted against false positive rate, is 0.706. As the value rages 
from 0 to 1, a value of 0.706 suggests good accuracy. The 
Matthew's correlation coefficient is 0.414. MCC measures the 
quality of binary classification and its values range from ‑1 to 
+1, where 0 is no better than random classification and +1 is 
perfect classification, thus a coefficient of 0.414 indicates fine 
selection between the groups. Further details of the method 
are within Table V.
Discussion
Glioblastoma, the most common glioma, has a poor prog-
nosis (1,2). Despite aggressive treatment protocols, patients 
Table IV. Mean immunohistochemistry scores of the ECM components that were determined to be significantly different in the 
two prognostic groups.
 Mean
 immunohistochemistry scores
 ---------------------------------------------------------
ECM component P-value Concordance with mRNA results Group A Group B
BCAN 0.0002 Yes 6.58 3.40
CD44 0.0200 Yes 4.35 3.69
HMMR 0.0020 Yes 5.71 3.58
ITGAV 0.0200 Yes 4.35 3.69
ITGβ1 0.0400 No 2.69 3.86
MDM2 0.0240 Yes 4.41 2.44 
Group A, OS <24 months; group B, OS >24 months; ECM, extracellular matrix; ITGAV, integrin-αV; BCAN, brevican; CD44, cluster of 
differentiation 44; HMMR, hyaluronan-mediated motility receptor; MDM2, murine double minute 2; OS, overall survival.
Table V. Characteristics of the binary classification that identified the prognostic group of each sample based upon the mRNA 
expression pattern of the extracellular matrix of the samples.
Class Sensitivity FP rate Positive prediction value F-1 score MCC ROC area
Group A 0.757 0.345 0.737 0.747 0.414 0.706
Group B 0.655 0.243 0.679 0.667 0.4144 0.706
Weighted mean 0.712 0.300 0.711 0.712 0.414 0.706 
Group A, OS <24 months; group B, OS >24 months; ROC, receiver operating curve; OS, overall survival; FP, false positive; F-1, F function 
score; MCC, Matthew's correlation coefficient.
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survive for only 16-24 months following diagnosis (37,38). 
Certain factors, like age or maximal safe tumor resection, are 
known to have a degree of association with patient survival; 
however, clinicians cannot assess individual prognosis (5-7). 
Glioma cells invade the neighboring tissue in a complex 
process actively influenced by ECM components (28,39). 
Previous studies determined that certain ECM molecules 
were expressed at an altered, frequently increased level in 
gliomas compared with that in non-tumor brain samples, and 
numerous studies determined that certain drugs designed to 
target these molecules can inhibit tumor invasion in vitro in 
certain subgroups of patients with glioblastoma (3,24,40-45). 
Bevacizumab is highly effective in one subgroup of patients, 
while other patients have reduced or no benefit from the 
targeted therapy (3,46,47). Furthermore, bevacizumab has 
been determined to exert its effect primarily in increasing PFS 
time, and it may not affect OS time significantly (48,49).
The present study aimed to analyze the ECM composition of 
glioblastoma samples in order to identify the expression pattern 
of patients with glioblastoma with ‘worse’ or ‘better’ survival. 
The two prognostic groups demonstrated differences in patient 
age at diagnosis, which is in accordance with literature data (5,6). 
No further differences were determined in terms of KPS score, 
tumor size or tumor location; therefore, it is possible that differ-
ences in survival are not explained by differences in clinical 
factors, as all patients had undergone the identical treatment 
Figure 4. Immunohistochemical images of glioblastoma stained for FLT4/VEGF-3. (A) Overexpression of FLT4/VEGF-3 in patients with glioblastoma with a 
worse prognosis. (B) Moderate positivity in patients with a better prognosis (staining is notably reduced compared with that in patients with a worse prognosis). 
(C) Negative control. All images depicted are at x20 magnification. FLT4, Fms‑related tyrosine kinase 4; VEGF, vascular endothelial growth factor.
Figure 6. Immunohistochemical images of glioblastoma stained for MMP-2. (A) MMP-2 positivity was notably strong in immunohistochemical images from 
patients with a worse prognosis, confirming the mRNA expression results. (B) Patients with a better prognosis expressed an increased amount of MMP‑2, 
as the strong positivity indicates, but the immunohistochemical scores are significantly reduced. (C) Negative control slide. All images are depicted at x20 
magnification. MMP‑2, matrix metallopeptidase 2.
Figure 5. Immunohistochemical images of glioblastoma stained for MDM2. (A) Immunhistochemical images from patients with a worse prognosis demon-
strated significantly increased positivity for MDM2, compared with (B) those with a better prognosis. (C) Negative control. All images are depicted at x20 
magnification. MDM2, murine double minute 2.
VIRGA et al:  ECM DIFFERENCES IN PATIENTS WITH VARYING GLIOBLASTOMA PROGNOSES804
policy; however, the survival times were notably different. 
Molecular methods were used to investigate differences in the 
molecular composition of the tumors with different prognoses.
It was determined that ECM components demonstrate 
differences in expression at transcriptional or translational 
levels. The mRNA expression of FLT4, MDM2 and MMP2 
genes was determined to be significantly different between the 
two groups. Additionally, MDM2 expression was determined 
to be significantly different at the protein level, while FLT4 and 
MMP‑2 were selected by the statistical classifier as key mole-
cules in the separation of different prognostic groups. Figs 4-6 
depict immunhistochemical slides stained with antibodies 
agains these ECM components. All 3 molecules exhibited 
increased expression in tumor samples from patients whose 
survival time was below average. These results supported 
previous data, further confirming their role in glioma inva-
sion (50,51). FLT4 is a receptor for VEGF-C and D, and it is 
not normally expressed in human brain endothelium; however, 
it has been previously determined to be overexpressed in 
the endothelium of blood vessels in glioblastoma (51). This 
expression may be responsible for the escape phenomenon of 
bevacizumab-treated patients, which is a secondary neovascu-
larization despite anti-angiogenic therapy with bevacizumab, 
which primarily inhibits VEGF1 and VEGF2, and partially 
inhibits VEGF3 (50). MDM2 is an inhibitor of the p53 protein. 
An increased amount of MDM2 can explain a second way 
method to bypass the gatekeeper function of p53 in tumor 
protein 53 wild-type glioblastomas (52,53). Furthermore, 
MDM2 has p53-independent roles. MDM2 may induce 
genomic instability through inhibiting DNA damage repair 
and suppressing cell cycle arrest (52). MDM2 has also been 
demonstrated to facilitate epithelial-mesenchymal transition; 
therefore, it enhances motility and tumor invasiveness (53). 
MMP2 has a well-described role in the dynamic alteration of 
tumor ECM, as well as other oncogenic functions that assist 
glioma cells with invading the brain parenchyma (54-57). All 
these molecules could serve as a target for future anti-invasive 
therapies in glioblastoma treatment.
In the present study, the statistical classifier nearest 
neighbor search was able to identify the prognostic group for 
each sample based upon the invasion spectrum, including the 
expressional pattern of the invasion-associated molecules. The 
method had high accuracy in determining whether the patient 
belonged to group A or B. This is important from a clinician's 
point of view, as it is one of the first methods that could provide 
information on individual patient survival. The increased posi-
tive predictive value for patients who have a worse prognosis 
is beneficial in identifying those patients that require extra 
attention and care, and whose treatment protocol should be 
intensified and/or complemented with targeted therapy as 
first‑line treatment. Additional information on the molecular 
composition of tumor samples is provided; thus, selecting the 
correct anti-invasive therapeutic agent in the future would be 
possible. Therefore, the invasion spectrum can be considered 
as a prognostic factor with a future predictive role in patients 
with glioblastoma.
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